“…Cytokines produced by T H 2 cells further drive IgE class switching of B cells, and the IgE antibodies crosslink mast cells/basophils through the high-affinity Fc receptor (FcεRI). During re-exposure, allergens with B-cell epitopes are captured by IgE on the surface of effector cells, resulting in degranulation that induces a series of allergic symptoms. , Thus, modifying B-cell epitopes to prevent binding to IgE while preserving T-cell epitopes to retain the ability of immunotherapy is the main strategy for immunotherapy . Studies have revealed epitopes in LYS that can be recognized by T cells, such as AA1–18, AA51–61, AA112–129, and AA107–116, , but reports on B-cell linear epitopes are relatively scarce, except for Jimenez-Saiz et al who obtained AA11–27, AA57–83, and AA108–122 with IgE binding activity based on mass spectrometry and Western blotting .…”